These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30914311)

  • 1. A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib.
    Zhu YC; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
    Clin Lung Cancer; 2019 May; 20(3):e224-e228. PubMed ID: 30914311
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
    Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
    Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
    [No Abstract]   [Full Text] [Related]  

  • 3. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
    Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract]   [Full Text] [Related]  

  • 4. BRAF
    Falcone R; Conte F; Fiscon G; Pecce V; Sponziello M; Durante C; Farina L; Filetti S; Paci P; Verrienti A
    Endocrine; 2019 May; 64(2):406-413. PubMed ID: 30850937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
    Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
    Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
    Chen Y; Chen B; Zhu X; Zhong J
    Lung Cancer; 2018 Feb; 116():96-98. PubMed ID: 29146159
    [No Abstract]   [Full Text] [Related]  

  • 7. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
    Zhu YC; Wang WX; Zhang QX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
    Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
    [No Abstract]   [Full Text] [Related]  

  • 8. BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.
    El Karak F; Assi T; Kourie HR; El Rassy E; Chebib R; Ghor M; Tabchi S
    Int J Clin Exp Pathol; 2015; 8(3):3294-8. PubMed ID: 26045855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 11. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
    Gautschi O; Peters S; Zoete V; Aebersold-Keller F; Strobel K; Schwizer B; Hirschmann A; Michielin O; Diebold J
    Lung Cancer; 2013 Nov; 82(2):365-7. PubMed ID: 24035431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer.
    Lucchesi C; Drogat B; Santamaria D; Cousin S; Italiano A
    Lung Cancer; 2018 Dec; 126():227-229. PubMed ID: 30342857
    [No Abstract]   [Full Text] [Related]  

  • 13. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
    Luo J; Gu D; Lu H; Liu S; Kong J
    J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
    [No Abstract]   [Full Text] [Related]  

  • 14. VPS41-BRAF, a novel BRAF fusion gene identified in a lung adenocarcinoma patient by next-generation sequencing.
    Wang L; Chen A; She X; Xiang J; Tang J
    Lung Cancer; 2020 Aug; 146():380-381. PubMed ID: 32527614
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.
    Zhu YC; Wang WX; Xu CW; Zhang QX; Du KQ; Chen G; Lv TF; Song Y
    Ann Oncol; 2018 Dec; 29(12):2392-2393. PubMed ID: 30339198
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
    Zhang Y; Yu M; Yuan M; Chen R; Huang MJ
    Clin Lung Cancer; 2020 Mar; 21(2):e78-e83. PubMed ID: 31722815
    [No Abstract]   [Full Text] [Related]  

  • 17. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
    Fei X; Zhu L; Zhou H; Qi C; Wang C
    J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.
    Hicks JK; Boyle T; Albacker LA; Madison R; Frampton G; Creelan BC
    J Thorac Oncol; 2018 Aug; 13(8):e148-e150. PubMed ID: 30049378
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of a novel LRRC4C-ALK fusion in lung adenocarcinoma and outcome of the response to anaplastic lymphoma kinase inhibitors.
    Wang H; Li Z; Qi X; Wang W; Lin Y
    J Gene Med; 2021 Mar; 23(3):e3316. PubMed ID: 33559138
    [No Abstract]   [Full Text] [Related]  

  • 20. A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.
    Boyle TA; Quinn GP; Schabath MB; Muñoz-Antonia T; Saller JJ; Duarte LF; Hair LS; Teer JK; Chiang DY; Leary R; Wong CC; Savchenko A; Singh AP; Charette L; Mendell K; Gorgun G; Antonia SJ; Chiappori AA; Creelan BC; Gray JE; Haura EB
    Cancer Med; 2020 Jan; 9(1):225-237. PubMed ID: 31747139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.